Literature DB >> 22898079

Silencing of miRNA-218 promotes migration and invasion of breast cancer via Slit2-Robo1 pathway.

Longqiu Yang1, Qing Li, Qingxiu Wang, Zhen Jiang, Lei Zhang.   

Abstract

MiRNAs play an important role in regulating tumor migration and invasion, and abnormal expression of miRNAs occurs in various kinds of human cancers. In this essay, it is reported that the level of miRNA-218 decreases in metastatic breast cancer cells, moreover, miRNA-218 suppresses breast cancer cells migration and invasion through binding Robo1 (one of Slit receptors) to its 3'UTR. MiRNA-218 restoration suppresses Robo1 expression and inhibits breast cancer cells invasion and migration. What the results describe is that the function of Robo1 regulated by miRNA-218 may provide a new strategy for inhibiting migration and invasion of breast cancer cells.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22898079     DOI： 10.1016/j.biopha.2012.04.006

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN： 0753-3322            Impact factor:   6.529


  15 in total

1.  MiR-622 suppresses proliferation, invasion and migration by directly targeting activating transcription factor 2 in glioma cells.

Authors:  Rui Zhang; Hui Luo; Shuai Wang; Zhengxin Chen; Lingyang Hua; Hong-Wei Wang; Wanghao Chen; Yongsheng Yuan; Xiaobin Zhou; Daqian Li; Shuying Shen; Tao Jiang; Yongping You; Ning Liu; Huibo Wang
Journal:  J Neurooncol       Date:  2014-09-26       Impact factor: 4.130

2.  MiR-202-5p/PTEN mediates doxorubicin-resistance of breast cancer cells via PI3K/Akt signaling pathway.

Authors:  Tao Liu; Jichao Guo; Xiaoxia Zhang
Journal:  Cancer Biol Ther       Date:  2019-04-14       Impact factor: 4.742

3.  Multi-omics analyses provide novel biological insights to distinguish lobular ductal types of invasive breast cancers.

Authors:  Ambily Sivadas; Victor C Kok; Ka-Lok Ng
Journal:  Breast Cancer Res Treat       Date:  2022-03-29       Impact factor: 4.872

4.  MicroRNA-544 inhibits glioma proliferation, invasion and migration but induces cell apoptosis by targeting PARK7.

Authors:  Shiguang Jin; Yan Dai; Cheng Li; Xiao Fang; Huijing Han; Daxin Wang
Journal:  Am J Transl Res       Date:  2016-04-15       Impact factor: 4.060

5.  MicroRNA-625 inhibits the proliferation and increases the chemosensitivity of glioma by directly targeting AKT2.

Authors:  Jiale Zhang; Jian Zhang; Jie Zhang; Wenjin Qiu; Shuo Xu; Qun Yu; Chengke Liu; Yingyi Wang; Ailin Lu; Junxia Zhang; Xiaoming Lu
Journal:  Am J Cancer Res       Date:  2017-09-01       Impact factor: 6.166

6.  miR-494-3p Regulates Cellular Proliferation, Invasion, Migration, and Apoptosis by PTEN/AKT Signaling in Human Glioblastoma Cells.

Authors:  Xue-Tao Li; Hang-Zhou Wang; Zhi-Wu Wu; Tian-Quan Yang; Zhao-Hui Zhao; Gui-Lin Chen; Xue-Shun Xie; Bin Li; Yong-Xin Wei; Yu-Lun Huang; You-Xin Zhou; Zi-Wei Du
Journal:  Cell Mol Neurobiol       Date:  2015-02-08       Impact factor: 5.046

Review 7.  microRNAs in axon guidance.

Authors:  Archana N Iyer; Anaïs Bellon; Marie-Laure Baudet
Journal:  Front Cell Neurosci       Date:  2014-03-14       Impact factor: 5.505

8.  MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway.

Authors:  Yuan Miao; Wei Zheng; Nana Li; Zhen Su; Lifen Zhao; Huimin Zhou; Li Jia
Journal:  Sci Rep       Date:  2017-02-06       Impact factor: 4.379

9.  MicroRNA-32 (miR-32) regulates phosphatase and tensin homologue (PTEN) expression and promotes growth, migration, and invasion in colorectal carcinoma cells.

Authors:  Weiyun Wu; Jingfang Yang; Xiao Feng; Hao Wang; Shicai Ye; Pengchun Yang; Wenkai Tan; Guoli Wei; Yu Zhou
Journal:  Mol Cancer       Date:  2013-04-23       Impact factor: 27.401

Review 10.  Focus on PTEN Regulation.

Authors:  Miriam Bermúdez Brito; Evangelia Goulielmaki; Evangelia A Papakonstanti
Journal:  Front Oncol       Date:  2015-07-27       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.